Deerfield Management TRDA Position
ExitedDeerfield Management exited their position in Entrada Therapeutics, Inc. (TRDA) in Q4 2024, after holding the stock for 2 quarters.
The position was first reported in Q3 2024 and has been tracked across 2 quarterly 13F filings.
2 other tracked funds also hold TRDA.
There is an upcoming Phase 2 readout for ENTR-601-45 in 1050 days (Mar 1, 2029), making the timing of Deerfield's position particularly relevant.
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Full company profile →Short Interest
4.4%
4.1 days to cover
Deerfield Management TRDA Position History
Frequently Asked Questions
Does Deerfield Management own TRDA?
No. Deerfield Management exited their position in Entrada Therapeutics, Inc. (TRDA) in Q4 2024. They previously held the stock for 2 quarters.
How many hedge funds own TRDA?
2 specialist biotech hedge funds currently hold TRDA, including Baker Bros. Advisors, Redmile Group. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy TRDA?
Deerfield Management's position in TRDA was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's TRDA position increasing or decreasing?
Deerfield Management completely exited their TRDA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TRDACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →